Rephonic
Artwork for Cell & Gene: The Podcast

Cell & Gene: The Podcast

Erin Harris
Gene Therapy
Cell and Gene Therapy
Clinical Trials
FDA
Rare Diseases
Solid Tumors
Cell Therapy
Parkinson's Disease
Duchenne Muscular Dystrophy
Gene Editing
Patient Access
Retinitis Pigmentosa
Cancer Treatment
Induced Pluripotent Stem Cells
Regenerative Medicine
Inherited Retinal Disorders
Autoimmune Diseases
CRISPR
Bluerock Therapeutics
Stargardt Disease

Cell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.

PublishesTwice monthlyEpisodes140Founded5 years ago
Number of ListenersCategories
ScienceLife Sciences

Listen to this Podcast

Artwork for Cell & Gene: The Podcast

Latest Episodes

We love to hear from our listeners. Send us a message.

For episode 131 of Cell & Gene: The Podcast, we’re sharing a recent "Better Biopharma" roundtable that Erin Harris had the opportunity to join alongside her Life Science Connect editorial collea... more

We love to hear from our listeners. Send us a message.

In Episode 3 of our in vivo-focused special series of Cell & Gene: The Podcast, Ascidian Therapeutics' Founder, President, and CEO Mike Ehlers, M.D., Ph.D., explains how the company is advancing... more

YouTube

We love to hear from our listeners. Send us a message.

In episode 2 of this four-part in vivo-focused special series of Cell & Gene: The Podcast, Host Erin Harris sits down with Gopi Shanker, Ph.D., Chief Scientific Officer at Beam Therapeutics, for... more

YouTube

We love to hear from our listeners. Send us a message.

In episode 130 of Cell & Gene: The Podcast, Dr. Naji Gehchan, Chief Medical and Development Officer at Kyverna Therapeutics, joins Host Erin Harris to outline the company’s mission to apply CAR ... more

YouTube

Key Facts

Accepts Guests
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Biotech Hangout
Biotech HangoutDaphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more
ASGCT Podcast Network
ASGCT Podcast NetworkAmerican Society of Gene & Cell Therapy

Recent Guests

Mike Ehlers
Founder, President and CEO of Ascidian Therapeutics
Ascidian Therapeutics
Episode: Why In Vivo Therapies Are Moving Toward the Clinic with Ascidian Therapeutics' Dr. Mike Ehlers
Gopi Shanker
Chief Scientific Officer at Beam Therapeutics
Beam Therapeutics
Episode: Reimagining In Vivo Gene Editing Through Base Editing and Targeted Delivery with Beam Therapeutics' Gopi Shanker, Ph.D.
Naji Gehchan
Chief Medical and Development Officer at Kyverna Therapeutics
Kyverna Therapeutics
Episode: Advancing CAR T for Drug-Free Remission in Autoimmune Disease with Kyverna Therapeutics’ Dr. Naji Gehchan
Cassie Gorsuch
CSO at Precision Biosciences
Precision Biosciences
Episode: The Future of In Vivo Gene Editing and Clinical Translation with Precision Biosciences' Cassie Gorsuch, Ph.D.
Zachary Roberts
Executive VP of Research & Development and Chief Medical Officer at Allogene Therapeutics
Allogene Therapeutics
Episode: Redefining CAR-T Timing and Patient Access with Allogene Therapeutics' Dr. Zachary Roberts
Tatyana Matveeva
Director of CGMP Operations at Massachusetts General Hospital and Harvard Medical School's Laboratory for Regenerative Cell Therapy
Massachusetts General Hospital / Harvard Medical School
Episode: Building Integrated cGMP Systems for Autologous Cell Therapies with MassGen's Tatyana Matveeva, Ph.D.
Carlos Buesa
Founder and CEO of Oryzon
Oryzon
Episode: Rewriting Disease Biology Through LSD1 Inhibition with Oryzon's Carlos Buesa, Ph.D.
Catriona Jamieson
Board-certified hematologist and leader in regenerative medicine
UC San Diego; Sanford Stem Cell Institute; UC San Diego Health
Episode: Advancing Early Detection in Rare Cancers with Catriona Jamieson, M.D., Ph.D.
Monika Swietlicka
Principal at Halloran Consulting Group
Halloran Consulting Group
Episode: Regulatory Flexibility in CGT: Key Shifts and Implications with Monika Swietlicka

Host

Erin Harris
Chief Editor of Cell & Gene, host of the show

Reviews

4.9 out of 5 stars from 70 ratings
  • Top Notch Podcast

    I’ve learned a great deal listening to this podcast. Erin Harris does a fantastic job of keeping the topics current and the guests she has on are all leaders in the industry.

    Apple Podcasts
    5
    buck025
    United States4 years ago
  • Must listen for anyone in this market

    If you’re interested in what the leaders of the cell therapy and gene therapy market think, this is well worth a subscribe.

    Apple Podcasts
    5
    Derek VS
    United States4 years ago
  • Required Listening

    The cell and gene space is growing and developing quickly. The Cell and Gene Podcast is the best way to keep up with this exciting and quickly developing segment of the pharma industry.

    Apple Podcasts
    5
    MoodyPooty
    United States4 years ago
  • Engaging and dynamic

    Engaging conversations about the fast growing cell and gene space

    Apple Podcasts
    5
    A. Dua
    United States4 years ago
  • Fantastic resource for the CGT sector

    Erin Harris does a great job facilitating concise and straight-to-the-point episodes on an impressive variety of topics and speakers. If you have a stake in the future of cell and gene therapies, then this podcast is a must.

    Apple Podcasts
    5
    Erie Train Fan
    United States4 years ago

Listeners Say

Key themes from listener reviews, highlighting what works and what could be improved about the show.

Content stays current with rapid developments in CGT and biopharma.
Guests are industry leaders who bring concise, actionable insights.
The host guides focused, high-signal conversations with experts.

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Talking Points

Recent interactions between the hosts and their guests.

The Future of In Vivo Gene Editing and Clinical Translation with Precision Biosciences' Cassie Gorsuch, Ph.D.
Q: From your perspective, what technological or biological barriers still stand between current capabilities and routine clinical success in in vivo gene editing?
Cassie explains that while momentum is high and preclinical programs are moving forward, delivery remains a central challenge, especially outside the liver where LNPs are less effective and AAVs have dose and redosing limitations. She emphasizes the importance of platform characteristics, such as Arcus being a single-component editor with small, efficiently packaged nucleases, which helps address both delivery and safety considerations. Selection of accurate preclinical models and translational data interpretation are also key to reducing translational gaps and informing dosing and safety profiles as programs move into clinic.
Advancing CAR T for Drug-Free Remission in Autoimmune Disease with Kyverna Therapeutics’ Dr. Naji Gehchan
Q: From your perspective, what does the outcome of patients discontinuing chronic immunotherapies suggest about the potential for CAR T therapies to shift autoimmune disease treatment away from lifelong disease management?
It demonstrates the core promise of Miv-cel and CAR T in autoimmune disease: durable, drug-free remission that reduces or eliminates the need for chronic therapies, which could redefine treatment goals and patient quality of life.
Why In Vivo Therapies Are Moving Toward the Clinic with Ascidian Therapeutics' Dr. Mike Ehlers
Q: Could you explain how your lead program for Stargardt disease works and what the current clinical status looks like?
The lead program, ACDN01, uses subretinal delivery of an RNA exon editor targeting ABCA4 in photoreceptors to correct mutations; dose escalation has been completed in the STELR study with encouraging safety signals, and expansion cohorts are anticipated.
Why In Vivo Therapies Are Moving Toward the Clinic with Ascidian Therapeutics' Dr. Mike Ehlers
Q: How does RNA exon editing change the therapeutic risk calculus compared to DNA editing?
RNA exon editing can be durable without being irreversible, which provides a different safety profile and reduces the risk exposure associated with permanent genomic changes.
Why In Vivo Therapies Are Moving Toward the Clinic with Ascidian Therapeutics' Dr. Mike Ehlers
Q: We know in vivo therapies are often talked about as the future of the field. What do you think still needs to be proven before they become mainstream?
The field needs to prove precision, durability, and predictability—being able to hit the right cells consistently, achieve meaningful biology, and maintain safety as programs scale beyond rare diseases into broader populations.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About Cell & Gene: The Podcast

What is Cell & Gene: The Podcast about and what kind of topics does it cover?

The show features high-level discussions with leaders in cell and gene therapy, often drawing on practical translational experience, regulatory perspectives, and cutting-edge science across oncology, rare diseases, hematology, and regenerative medicine. Episodes frequently center on CGMP operations, scalable manufacturing, regulatory strategy, and novel therapeutic modalities such as CRISPR, CAR-T, and gene-agnostic platforms, with guests ranging from hospital program leaders to biotech CEOs and regulatory experts. Noteworthy is the emphasis on practical pathways from lab to clinic, patient access, and the evolving regulatory landscape, which helps sponsors and guests understand how to move innovative therapies forward efficiently. The prog... more

Where can I find podcast stats for Cell & Gene: The Podcast?

Rephonic provides a wide range of podcast stats for Cell & Gene: The Podcast. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to Cell & Gene: The Podcast and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does Cell & Gene: The Podcast get?

Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for Cell & Gene: The Podcast, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for Cell & Gene: The Podcast?

Rephonic provides comprehensive predictive audience data for Cell & Gene: The Podcast, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does Cell & Gene: The Podcast have?

To see how many followers or subscribers Cell & Gene: The Podcast has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to Cell & Gene: The Podcast?

These podcasts share a similar audience with Cell & Gene: The Podcast:

1. BioCentury This Week
2. The Readout Loud
3. Biotech Hangout
4. The Long Run with Luke Timmerman
5. ASGCT Podcast Network

How many episodes of Cell & Gene: The Podcast are there?

Cell & Gene: The Podcast launched 5 years ago and published 140 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact Cell & Gene: The Podcast?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for Cell & Gene: The Podcast?

Rephonic pulls ratings and reviews for Cell & Gene: The Podcast from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for Cell & Gene: The Podcast?

Rephonic provides full transcripts for episodes of Cell & Gene: The Podcast. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on Cell & Gene: The Podcast?

Recent guests on Cell & Gene: The Podcast include:

1. Mike Ehlers
2. Gopi Shanker
3. Naji Gehchan
4. Cassie Gorsuch
5. Zachary Roberts
6. Tatyana Matveeva
7. Carlos Buesa
8. Catriona Jamieson

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days